abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

Esta página no está disponible en Español y está siendo mostrada en English

Artículo

13 Jun 2007

Autor:
Novartis

[DOC] Improving Indian patent law benefits patients and societies

We have received concerns regarding our ongoing legal challenge against one provision of the Indian Patent Act, following the denial of the patent for our ground-breaking cancer treatment Glivec®/Gleevec®. We have heard these concerns and want to clarify our perspective.

Línea del tiempo